药品注册申请号:050709
申请类型:NDA (新药申请)
申请人:ASTELLAS
申请人全名:ASTELLAS PHARMA US INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 PROGRAF TACROLIMUS INJECTABLE;INJECTION EQ 5MG BASE/ML Yes Yes AP 1994/04/08 1994/04/08 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2022/11/22 SUPPL-47(补充) Approval Labeling STANDARD
2021/07/16 SUPPL-45(补充) Approval Efficacy PRIORITY ;Orphan
2020/12/30 SUPPL-44(补充) Approval Labeling STANDARD
2019/06/11 SUPPL-42(补充) Approval Labeling STANDARD
2018/12/02 SUPPL-41(补充) Approval Labeling STANDARD
2018/05/24 SUPPL-40(补充) Approval Labeling STANDARD
2015/07/01 SUPPL-37(补充) Approval Manufacturing (CMC) PRIORITY
2015/05/19 SUPPL-38(补充) Approval Labeling STANDARD
2013/09/04 SUPPL-36(补充) Approval Labeling STANDARD ;Orphan
2013/08/16 SUPPL-35(补充) Approval Manufacturing (CMC) PRIORITY
2012/08/14 SUPPL-34(补充) Approval Labeling STANDARD
2012/07/05 SUPPL-33(补充) Approval Labeling STANDARD
2012/02/06 SUPPL-31(补充) Approval Labeling STANDARD
2011/07/14 SUPPL-30(补充) Approval Labeling UNKNOWN
2011/07/14 SUPPL-28(补充) Approval Labeling STANDARD
2009/05/19 SUPPL-21(补充) Approval Efficacy PRIORITY
2009/02/13 SUPPL-26(补充) Approval Labeling STANDARD
2006/04/27 SUPPL-20(补充) Approval Labeling STANDARD
2006/03/29 SUPPL-19(补充) Approval Efficacy STANDARD
2005/12/13 SUPPL-18(补充) Approval Labeling STANDARD
2004/06/16 SUPPL-13(补充) Approval Labeling STANDARD
2001/07/25 SUPPL-12(补充) Approval Labeling STANDARD
2000/12/01 SUPPL-10(补充) Approval Efficacy STANDARD
1998/04/20 SUPPL-7(补充) Approval Manufacturing (CMC) PRIORITY
1997/04/22 SUPPL-6(补充) Approval Efficacy STANDARD
1997/04/22 SUPPL-5(补充) Approval Efficacy STANDARD
1996/04/25 SUPPL-4(补充) Approval Labeling STANDARD
1995/06/22 SUPPL-3(补充) Approval Manufacturing (CMC) PRIORITY
1994/04/08 ORIG-1(原始申请) Approval Type 3 - New Dosage Form PRIORITY ;Orphan
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 5260301 2011/02/28 Y PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 ODE-360 2028/07/16
ODE-294 2025/05/24
001 ODE 2013/03/29**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:TACROLIMUS 剂型/给药途径:INJECTABLE;INJECTION 规格:EQ 5MG BASE/ML 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
050709 001 NDA PROGRAF TACROLIMUS INJECTABLE;INJECTION EQ 5MG BASE/ML Prescription Yes Yes AP 1994/04/08 ASTELLAS
203900 001 ANDA TACROLIMUS TACROLIMUS INJECTABLE;INJECTION EQ 5MG BASE/ML Discontinued No No AP 2017/08/25 HOSPIRA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database